[HTML][HTML] Longitudinal symptom dynamics of COVID-19 infection
…, K Marcus, Y Barer, A Keshet, N Shamir-Stein… - Nature …, 2020 - nature.com
As the COVID-19 pandemic progresses, obtaining information on symptoms dynamics is of
essence. Here, we extracted data from primary-care electronic health records and nationwide …
essence. Here, we extracted data from primary-care electronic health records and nationwide …
Effectiveness of a third dose of BNT162b2 mRNA vaccine
Y Saciuk, J Kertes, N Shamir Stein… - The Journal of …, 2022 - academic.oup.com
A retrospective cohort study was carried out in a large Israeli health maintenance organization
to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against …
to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against …
Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
…, A Kantor, L Adler, N Shamir Stein… - Clinical Infectious …, 2023 - academic.oup.com
Background Intramuscular AZD7442 (tixagevimab–cilgavimab [Evusheld; AstraZeneca])
has been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV-…
has been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV-…
[HTML][HTML] Immediate side effects of Comirnaty COVID-19 vaccine: A nationwide survey of vaccinated people in Israel, December 2020 to March 2021
…, SB Gez, D Rahamim-Cohen, N Shamir-Stein… - …, 2022 - eurosurveillance.org
… Na’ama Shamir-Stein and Anat Ekka Zohar perceived and designed the study. Material
preparation, data collection and analysis were performed by Shirley Shapiro Ben David, Sharon …
preparation, data collection and analysis were performed by Shirley Shapiro Ben David, Sharon …
Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors-A nationwide survey
SSB David, N Shamir-Stein, SB Gez, U Lerner… - Clinical …, 2021 - Elsevier
Background Since July 13, 2021, a third SARS-CoV-2 vaccine BNT162b2 was approved in
Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate …
Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate …
Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel
Abstract Development of an effective vaccine against Covid-19 is crucial to reducing infection.
mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first …
mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first …
[HTML][HTML] Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel
J Kertes, SB Gez, Y Saciuk… - Emerging infectious …, 2022 - ncbi.nlm.nih.gov
Israel experienced a new wave of coronavirus disease during June 2021, six months after
implementing a national vaccination campaign. We conducted 3 discrete analyses using data …
implementing a national vaccination campaign. We conducted 3 discrete analyses using data …
Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
J Kertes, SSB David, N Engel-Zohar… - … diseases: an official …, 2022 - ncbi.nlm.nih.gov
Background Intramuscular AZD7442 (Tixagevimab–Cilgavimab,(Evusheld)) has been found
effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection …
effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection …
[HTML][HTML] Post-acute sequelae of COVID-19 infection
…, SBD Shirley, P Avi, RC Daniella, SS Naama… - Preventive medicine …, 2023 - Elsevier
To determine if people infected with SARS-CoV-2 were at higher risk of developing selected
medical conditions post-recovery, data were extracted from the database of a large health …
medical conditions post-recovery, data were extracted from the database of a large health …
[HTML][HTML] Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study
…, S Shapiro Ben David, A Shahar, N Shamir-Stein… - Biomedicines, 2023 - mdpi.com
Background: Risk stratification models have been developed to identify patients that are at a
higher risk of COVID-19 infection and severe illness. Objectives To develop and implement …
higher risk of COVID-19 infection and severe illness. Objectives To develop and implement …
